Alcohol-associated liver disease has increased over the last year. It is needed to understand the changes in trends, factors affecting this, and potential interventions.

ALD is one of the most common causes of liver disease. Early identification is key. This MTEs session will discuss screening strategies and how to identify ALD at a population level

The purpose of this session is to discuss management of co-morbid viral and liver disease in patients living with hepatitis C. The experts will discuss their approach to hepatitis C treatment and post-treatment management in patients with concomitant HIV,

Disparities in health care are associated with worse health outcomes and occur globally in the context of broader inequity. There are many contributors to disparities across health systems, providers and patients, respectively. This session will introduce

In this session the possibilities for monitoring and treating hepatitis delta patients will be discussed. With new agents appearing there will be more possibilities for treating hepatitis delta patients with either suppressive or better curative therapies

This session will review the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies.  There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indication

The purpose of this session is to discuss the unique challenges and opportunities for hepatitis C management in correctional facilities.

This session will discuss the current understanding, updates, and future directions related to immunology in ALD

Despite the anticipated FDA approval of the first MASH drug by the end of 2023, lifestyle interventions aiming at significant weight loss will remain cornerstone therapy for this disease. So far dietary interventions at large scale have failed to show sus